Humate-P (antihemophilic factor, human/von Willebrand factor,human)

Advertisement

Last reviewed · Source: First Databank (FDB) drug data

Overview

Antihemophilic factor (human) is a preparation of antihemophilic factor (blood coagulation factor VIII) prepared from pooled human plasma. Antihemophilic factor/von Willebrand factor complex (human) is a preparation of antihemophilic factor and von Willebrand factor prepared from pooled human plasma.

USES: This product contains human factor VIII (also called antihemophilic factor) and von Willebrand factor complex. Factors are proteins normally found in the blood that help the blood to thicken (clot) and stop any bleeding. People with low levels of factor VIII and von Willebrand factor are at risk for bleeding longer after an injury/surgery and for bleeding inside the body (especially into the joints and muscles).

This product is used to temporarily replace the missing factors and reduce bleeding. Different brands of this product have different amounts of these factors, and so have different uses. These products are not interchangeable.

Do not change brands of this medication without the approval of your doctor. Some products are used to control and prevent bleeding episodes in people with low levels of factor VIII (hemophilia A). Some products are used to control and prevent bleeding episodes in people with low levels of von Willebrand factor (von Willebrand disease).

Some products are used to prevent excessive bleeding during and after surgery in patients with von Willebrand disease.

Generic name: antihemophilic factor, human/von Willebrand factor,human
Pronunciation: (FAK-tor VIII/von-WIL-e-brand FAK-tor)

Reference product & biosimilars

No reference, biosimilar or interchangeable associated with this drug.

Today’s intelligence on Humate-P

Intelligence content is not available yet.

Indications

The following indications are listed for Humate-P:

  • Acquired Factor Viii Deficiency Disease
  • Bleeding Episode In Acquired Factor Viii Deficiency Disease
  • Bleeding Episode In Hemophilia A
  • Bleeding Prevention In Von Willebrand Disease Type 3
  • Hemophilia A
  • Prevention Of Surgery-Induced Bleed In Von Willebrand's Disease
  • Von Willebrand's Disease

Also known as: Angiohemophilia, Bleeding Prophylaxis In Type 3 Von Willebrand Disease, Congenital Factor Viii Deficiency Disease, Constitutional Thrombopathy, Hemorrhaging In Hemophilia A, Pseudohemophilia, Vascular Hemophilia, Von Willebrand Disease, Willebrand-Juergens Disease.

Dosing

Dosage of antihemophilic factor (human) and antihemophilic factor/von Willebrand factor complex (human) is expressed in terms of international units (IU, units); 1 unit of antihemophilic factor is approximately equivalent to the amount of factor VIII in 1 mL of fresh pooled human plasma. In general, administration of 1 unit/kg of these antihemophilic factor preparations will increase the circulating factor VIII level by approximately 2 units/dL (2%).

Drug interactions

There is no enhanced messaging for this drug.

Contraindications

There is no enhanced messaging for this drug.

Adverse reactions

There is no enhanced messaging for this drug.

Precautions

No enhanced messaging available.

ICD codes

No ICD codes are available for this drug.

Formulary status

Search health-plan coverage for this drug by ZIP code.

Enter a ZIP code to view available health plans.

Last reviewed · Source: First Databank (FDB) drug data